Prospective Lifespan Cohort of Myocardial Infarction

Starting soon

Conditions studied: Acute Myocardial Infarction (AMI), Stable Angina, Unstable Angina

In brief

This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management. The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up. The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.

Key facts

Study ID

NCT07471763

Run by

Fujian Provincial Hospital

People needed

6000

Starts

2026-04-10

Expected to finish

2031-04-10

Last updated by the study team

2026-03-25

Who can join

Age: 18 and older, up to 74. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 74 years
• Diagnosed with stable angina, unstable angina, or acute myocardial infarction
• For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized
• Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction
• Willing to participate and able to provide written informed consent
• Able to complete baseline assessment, biospecimen collection, and long-term follow-up

You may not qualify if…

• End-stage malignant tumor with expected survival of less than 1 year
• Severe hepatic or renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m² or Child-Pugh class C)
• Active autoimmune disease or long-term use of immunosuppressive agents
• Pregnant or breastfeeding women
• Inability to provide informed consent or severe cognitive impairment
• Previous participation in another clinical study that may conflict with this project
• Any other condition considered by the investigators to make participation inappropriate

Where it is running

• Fuzhou University Affiliated Provincial Hospital — Fuzhou, Fujian, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.